A Phase 1 Safety Study in Adults With Schizophrenia
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study will determine the safety, tolerability, and pharmacokinetics (PK) of olanzapine
and samidorphan in adults with schizophrenia following 14 consecutive days of oral
administration of ALKS 3831.